{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:33:12Z","timestamp":1777638792205,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Due to the recognized biological role of nitric oxide (NO) donating derivatives and of selective inhibitors of specific human carbonic anhydrase isoforms (CA, EC 4.2.1.1), promising compounds having an aromatic\/heterocyclic primary sulfonamide and functionalized with NO-releasing moieties have been designed. These bifunctional agents have been tested in vitro and in vivo to assess their dual pharmacological activity. According to the encouraging results they could be proposed for the treatment of angle-open glaucoma, cancer regression and osteoporosis, in which both NO and CA activities are involved.<\/jats:p>","DOI":"10.3390\/molecules20045667","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T03:47:46Z","timestamp":1428378466000},"page":"5667-5679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Nitric Oxide Donors and Selective Carbonic Anhydrase Inhibitors: A Dual Pharmacological Approach for the Treatment of Glaucoma, Cancer and Osteoporosis"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-9440","authenticated-orcid":false,"given":"Simone","family":"Carradori","sequence":"first","affiliation":[{"name":"Department of Pharmacy, \"G. D'Annunzio\" University of Chieti-Pescara, Via dei Vestini 31,  66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Mollica","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, \"G. D'Annunzio\" University of Chieti-Pescara, Via dei Vestini 31,  66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"De Monte","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Granese","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu","family":"Supuran","sequence":"additional","affiliation":[{"name":"Laboratorio di Chimica Bioinorganica, Universit\u00e0 degli Studi di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Firenze), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0707224","article-title":"Recent developments in nitric oxide donor drugs","volume":"151","author":"Miller","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(94)90267-4","article-title":"NO at Work","volume":"78","author":"Schmidt","year":"1994","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1389557053402684","article-title":"Focus on recent approaches for the development of new NO-donors","volume":"5","author":"Gasco","year":"2005","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/092986712803414321","article-title":"Nitric oxide: State of the art in drug design","volume":"19","author":"Serafim","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1749-6632.2002.tb04080.x","article-title":"Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents","volume":"962","author":"Burgaud","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1039\/c2cs15273h","article-title":"Nitric oxide release: Part II. Therapeutic applications","volume":"41","author":"Carpenter","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/14756366.2012.672983","article-title":"Structure-based drug discovery of carbonic anhydrase inhibitors","volume":"27","author":"Supuran","year":"2012","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14756366.2012.658788","article-title":"Secondary\/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II","volume":"28","author":"Alp","year":"2013","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejmech.2014.07.014","article-title":"Cyclic tertiary sulfamates: Selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives","volume":"84","author":"Carradori","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.bmc.2014.06.003","article-title":"Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: Synthesis, biological evaluation and molecular modelling studies","volume":"22","author":"Carradori","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.bmc.2014.01.056","article-title":"Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII","volume":"22","author":"Carradori","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1039\/C4CC07320G","article-title":"An out of the active site binding pocket for carbonic anhydrase inhibitors","volume":"51","author":"Carradori","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gidaro, M.C., Alcaro, F., Carradori, S., Costa, G., Vullo, D., Supuran, C.T., and Alcaro, S. (2015). Eriocitrin and apigenin as new carbonic anhydrase V A inhibitors, from a virtual screening of Calabrian natural products. Planta Med.","DOI":"10.1055\/s-0034-1396139"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.bmcl.2013.10.026","article-title":"Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII\u2014A new scaffold for designing isoform-selective inhibitors","volume":"23","author":"Carradori","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14756366.2011.597749","article-title":"A new approach to antiglaucoma drugs: Carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology","volume":"27","author":"Fabrizi","year":"2012","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/0042-6989(96)00017-X","article-title":"Nitric oxide: A review of its role in retinal function and disease","volume":"36","author":"Goldstein","year":"1996","journal-title":"Vis. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): An emerging target for the treatment of glaucoma","volume":"55","author":"Cavet","year":"2014","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-94-007-7359-2_17","article-title":"Glaucoma and the applications of carbonic anhydrase inhibitors","volume":"75","author":"Scozzafava","year":"2014","journal-title":"Subcell. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543776.2012.649006","article-title":"Novel therapies for glaucoma: A patent review 2007\u20132011","volume":"22","author":"Carta","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1016\/j.bmcl.2011.04.046","article-title":"Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action","volume":"21","author":"Mincione","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1016\/j.bmcl.2009.10.036","article-title":"Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma","volume":"19","author":"Steele","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1016\/j.bmc.2010.03.082","article-title":"NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II","volume":"18","author":"Ekinci","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","unstructured":"Botr\u00e8, F., Gros, G., and Storey, B.T. (1991). Carbonic Anhydrase-From Biochemistry and Genetics to Physiology and Clinical Medicine, VCH."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Supuran, C.T., and Winum, J.Y. (2009). Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Wiley.","DOI":"10.1002\/9780470508169"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1016\/j.bmc.2013.08.033","article-title":"Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases","volume":"21","author":"Pinard","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543776.2013.794788","article-title":"Antiglaucoma carbonic anhydrase inhibitors: A patent review","volume":"23","author":"Masini","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.niox.2008.04.023","article-title":"Nitric oxide\u2014A novel therapeutic for cancer","volume":"19","author":"Coulter","year":"2008","journal-title":"Nitric Oxide"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbrc.2013.01.041","article-title":"Applications for nitric oxide in halting proliferation of tumor cells","volume":"431","author":"Reynolds","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.07.014","article-title":"Nitric oxide in cancer metastasis","volume":"353","author":"Cheng","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.niox.2008.04.019","article-title":"Role of S-nitrosylation in apoptosis resistance and carcinogenesis","volume":"19","author":"Iyer","year":"2008","journal-title":"Nitric Oxide"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00198-012-2262-9","article-title":"The effects of organic nitrates on osteoporosis: A systematic review","volume":"24","author":"Jamal","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.archoralbio.2014.09.012","article-title":"Zolendronate inhibits receptor activator of nuclear factor kappa-B ligand induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2","volume":"60","author":"Nakagawa","year":"2014","journal-title":"Arch. Oral. Biol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/4\/5667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:44:10Z","timestamp":1760215450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/4\/5667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,31]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"alternative-id":["molecules20045667"],"URL":"https:\/\/doi.org\/10.3390\/molecules20045667","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,31]]}}}